Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Report Detailing Association Between Risperidone, Development of Gynecomastia in Men

New York, New York (PRWEB) August 08, 2014

As Risperdal lawsuits ( mount in U.S. courts, Bernstein Liebhard LLP notes that yet another group of researchers has found data to support a link between exposure to risperidone, the active ingredient in the atypical antipsychotic drug, and the development of gynecomastia (male breast growth) in men. Writing in the August 6th issue of the Journal of Clinical Psychopharmacology, scientists from University of British Columbia reported that they had looked at health records for over 82,000 men aged 40 to 85 years between 2001 and 2011, and found that 27 of 174 of the men exposed to risperidone developed gynecomastia within 60 days. They concluded that men using this drug were more likely to develop the condition compared to those using other atypical antipsychotics, as well as non-users of the medications. They also noted that their findings were consistent with the number of reported cases of gynecomastia involving atypical antipsychotic drugs that have been reported to U.S. Food & Drug Administration, which also indicate that reports involving risperidone are the most frequent.*

“Our Firm is representing a number of plaintiffs in Risperdal lawsuits that claim the drug caused gynecomastia. This report just adds to a growing body of evidence that support the allegations put forth in these and other claims,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Gynecomastia Allegations
Risperdal is an atypical antipsychotic drug used to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder. Research also indicates that off- label use of Risperdal to treat ADHD is also on the rise.**

The report published this month by the University of British Columbia researchers is just the latest to implicate Risperdal in the development of gynecomastia. According to research published in 2006 in the same journal, Risperdal may cause the body to produce excessive amounts of a hormone called prolactin, which is known to stimulate breast growth and milk production in women. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the authors of that study. ***

Court documents indicate that hundreds of plaintiffs are currently pursuing Risperdal lawsuits for gynecomastia allegedly caused by the medication. The majority of these claims are pending in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing cases. Among other things, the complaints accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing the association between Risperdal and male breast growth, and of improperly marketing the drug for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).

On November 4th, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.2 billion to resolve criminal and civil charges stemming from their marketing of Risperdal and other drugs. Among other things, federal prosecutors had alleged that the companies marketed Risperdal for pediatric uses long before it was approved for such indications in 2006. According to court documents filed in the case, the Justice Department had also charged that the company concealed side effects associated with the medication, including an association between Risperdal and elevated levels of prolactin. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Individuals who were treated with Risperdal are urged to contact Bernstein Liebhard LLP for a free legal consultation if they developed gynecomastia or male breast growth while taking this drug. To learn more about filing a Risperdal lawsuit, please contact the Firm by calling 800-511-5092.

*, Journal of Clinical Psycopharmacology
**, U.S. News & World Report, August 7, 2012
***, Journal of Clinical Psychopharmacology, April 2006

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuits Mount, With Filing of New Gynecomastia Complaint in New York Federal Court, Bernstein Liebhard LLP Reports
2. Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports
3. Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports
4. New Risperdal Lawsuit Website Published by Bernstein Liebhard LLP; Provides Side Effect Information, Litigation Updates
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes New Report Detailing Increasing Use of Risperdal and other Antipsychotic Drugs Among Children
6. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
7. Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies
8. As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
9. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
11. As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Launches Website to Provide Information Regarding Alleged Association Between Risperdal and Gynecomastia
Post Your Comments:
(Date:12/1/2015)... ... , ... Integrated Rental Services (“Integrated Rental”), a growing medical ... , With support from JII, Integrated Rental is poised for expansion while improving ... research labs and medical facilities across the United States. , General Manager Robert ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... we have seen vast improvements in scientific research and discoveries, leading us to ... increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
(Date:12/1/2015)... 1, 2015  AccuTEC Blades, a leader in ... logo and brand identity program. The new logo ... of bladed products where "the edge makes all ... --> Serving manufacturers and distributors of medical, ... equipment, AccuTEC,s product lines include those acquired when ...
Breaking Medicine Technology: